From: Multi-omics gut microbiome signatures in obese women: role of diet and uncontrolled eating behavior
 | All | NW | OB |  | |||||
 | N | Median (p25-p75) | N | Median (p25-p75) | N | Median (p25-p75) | p | ||
Anthropometric, biochemical, and hormonal parameters | |||||||||
 Age (years) | 100 | 34 (26–43) | 37 | 33 (27–41) | 63 | 38 (27–45) | 0.240 | ||
 Body weight (kg) | 100 | 75.3 (62.1–84.0) | 37 | 58.0 (53.8–64.1) | 63 | 81.0 (76.0–90.0) |  < 0.001 | ||
 Body mass index, BMI (kg/m2) | 100 | 28.1 (22.8–32.8) | 37 | 21.6 (20.1–23.1) | 63 | 30.9 (28.3–33.9) |  < 0.001 | ||
 Systolic blood pressure (mmHg) | 99 | 120.0 (110.0–130.0) | 37 | 110.0 (110.0–120.0) | 62 | 120.0 (110.0–130.0) | 0.001 | ||
 Diastolic blood pressure (mmHg) | 99 | 70.0 (70.0–80.0) | 37 | 70.0 (65.0–73.0) | 62 | 80.0 (70.0–80.0) |  < 0.001 | ||
 Waist circumference (cm) | 100 | 95.0 (84.0–103.0) | 37 | 80.0 (73.5–86.5) | 63 | 101.0 (95.0–107.0) |  < 0.001 | ||
 Hip circumference (cm) | 88 | 106.0 (97.3–115.0) | 37 | 96.0 (91.5–100.0) | 51 | 115.0 (107.0–121.0) |  < 0.001 | ||
 Waist-to-hip ratio | 88 | 0.86 (0.81–0.91) | 37 | 0.82 (0.79–0.88) | 51 | 0.89 (0.83–0.94) |  < 0.001 | ||
 Total cholesterol (mg/dl) | 100 | 180.0 (162.0–204.0) | 37 | 169.0 (160.0–192.0) | 63 | 191.0 (162.0–211.0) | 0.044 | ||
 HDL-cholesterol (mg/dl) | 100 | 54.5 (46.3–62.8) | 37 | 59.0 (52.5–65.0) | 63 | 52.0 (44.0–59.0) | 0.003 | ||
 Triglycerides (mg/dl) | 100 | 71.0 (53.3–99.8) | 37 | 57.0 (45.5–71.0) | 63 | 87.0 (59.0–110.0) |  < 0.001 | ||
 LDL-cholesterol (mg/dl) | 97 | 110.0 (96.5–130.5) | 37 | 105.0 (95.0–116.5) | 60 | 114.0 (97.3–140.8) | 0.141 | ||
 Glycemia (mg/dl) | 100 | 86.0 (80.0–90.0) | 37 | 81.0 (79.0–85.5) | 63 | 89.0 (82.0–93.0) |  < 0.001 | ||
 Glycemia-AUC (mg/dl) | 98 | 12,930 (10,901–14,632) | 37 | 11,130 (10,275–12,735) | 61 | 14,085 (12,495–16,050) |  < 0.001 | ||
 Insulin (μU/ml) | 100 | 6.8 (4.2–12.0) | 37 | 3.7 (3.0–5.0) | 63 | 10.1 (6.0–14.0) |  < 0.001 | ||
 Insulin-AUC (μU/ml) | 97 | 5110 (3500–8017) | 37 | 3412 (2472–4326) | 60 | 7163 (4750–9966) |  < 0.001 | ||
 Glycated hemoglobin (%) | 100 | 5.2 (4.9–5.4) | 37 | 5.0 (4.8–5.2) | 63 | 5.3 (5.1–5.4) |  < 0.001 | ||
 Creatinine (mg/dl) | 45 | 0.73 (0.63–0.83) | 3 | 0.67 (0.58–0.73)* | 42 | 0.74 (0.64–0.84) | 0.300 | ||
 Alanine transaminase, ALT (mg/dl) | 46 | 17.5 (12.0–24.0) | 3 | 7.0 (6.0–24.0)* | 43 | 18.0 (13.0–24.0) | 0.163 | ||
 Aspartate transaminase, AST (mg/dl) | 46 | 16.0 (14.0–20.0) | 3 | 14.0 (13.0–23.0)* | 43 | 16.0 (14.0–20.0) | 0.643 | ||
 Uric acid (mg/dl) | 43 | 4.3 (3.7–4.8) | 3 | 3.4 (2.8–3.9)* | 40 | 4.3 (3.9–4.9) | 0.020 | ||
 Erythrosedimentation rate (mm/h) | 44 | 11.5 (6.0–19.8) | 3 | 2.0 (2.0–4.0)* | 41 | 13.0 (7.0–20.0) | 0.002 | ||
 C-reactive protein (mg/dl) | 43 | 0.3 (0.1–0.5) | 3 | 0.03 (0.03–0.07)* | 40 | 0.3 (0.1–0.5) | 0.004 | ||
 Thyroid stimulating hormone, TSH (mUI/ml) | 48 | 1.56 (1.30–2.11) | 4 | 1.88 (1.48–2.94) | 44 | 1.53 (1.11–2.11) | 0.395 | ||
 Adrenocorticotropic hormone, ACTH (pg/ml) | 45 | 17.0 (12.0–23.0) | 3 | 11.0 (11.0–17.0)* | 42 | 17.5 (12.8–23.0) | 0.122 | ||
 HOMA-IR | 100 | 1.43 (0.83–2.66) | 37 | 0.74 (0.61–0.99) | 63 | 2.16 (1.34–3.25) |  < 0.001 | ||
 Matsuda Index | 92 | 5.75 (3.62–9.47) | 32 | 10.3 (7.88–15.08) | 60 | 4.05 (2.83–5.83) |  < 0.001 | ||
 | N | Mean ± sd | N | Mean ± sd | N | Mean ± sd | p | ||
Psychometric parameters | Â | Â | Â | Â | Â | ||||
 BITE severity score | 88 | 4.48 ± 4.51 | 33 | 1.75 ± 1.27 | 55 | 6.11 ± 4.96 |  < 0.001 | ||
 BITE symptom score | 88 | 6.53 ± 5.85 | 33 | 5.39 ± 3.43 | 55 | 7.21 ± 6.85 | 0.158 | ||
 TFEQ UE | 90 | 16.94 ± 5.39 | 33 | 15.97 ± 4.93 | 57 | 17.51 ± 5.61 | 0.193 | ||
 TFEQ CR | 90 | 14.35 ± 4.29 | 33 | 12.24 ± 2.90 | 57 | 15.58 ± 4.50 |  < 0.001 | ||
 TFEQ EE | 90 | 7.56 ± 2.99 | 33 | 5.73 ± 2.22 | 57 | 8.65 ± 2.87 |  < 0.001 | ||
 YFAS symptoms | 100 | 2.28 ± 1.55 | 37 | 1.08 ± 0.54 | 63 | 2.98 ± 1.52 |  < 0.001 | ||
 YFAS diagnosed addiction (a) | 14 | 14% | 37 | 0 | 63 | 14 |  < 0.001 | ||
 PSS | 96 | 15.53 ± 6.39 | 35 | 14.2 ± 5.19 | 61 | 16.29 ± 6.91 | 0.123 |